These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12782643)

  • 1. Pharmacological modulation of platelet function in hypertension.
    Blann AD; Nadar S; Lip GY
    Hypertension; 2003 Jul; 42(1):1-7. PubMed ID: 12782643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet activation in essential hypertension: implications for antiplatelet treatment.
    Gkaliagkousi E; Passacquale G; Douma S; Zamboulis C; Ferro A
    Am J Hypertens; 2010 Mar; 23(3):229-36. PubMed ID: 20094035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet activation in the hypertensive disorders of pregnancy.
    Nadar S; Lip GY
    Expert Opin Investig Drugs; 2004 May; 13(5):523-9. PubMed ID: 15155127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
    Sepúlveda C; Palomo I; Fuentes E
    Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of platelet activation-inhibitory drugs.
    Rao GH; Rao AT
    Indian J Physiol Pharmacol; 1994 Apr; 38(2):69-84. PubMed ID: 8063366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension.
    Remková A; Kratochvíl'ová H
    J Hum Hypertens; 2002 Aug; 16(8):549-55. PubMed ID: 12149660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension.
    Islim IF; Bareford D; Beevers DG
    Platelets; 2001 Aug; 12(5):274-8. PubMed ID: 11487379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is hypertension a prothrombotic state?
    Varughese GI; Lip GY
    Curr Hypertens Rep; 2005 Jun; 7(3):168-73. PubMed ID: 15913489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet monitoring for PCI: is it really necessary?
    Tantry US; Gurbel PA
    Hamostaseologie; 2009 Nov; 29(4):368-75. PubMed ID: 19882080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
    Nadar S; Blann AD; Lip GY
    Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence?
    Winther K; Gleerup G; Hedner T
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S21-4. PubMed ID: 1376829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal platelet activation profile in patients with peripheral arterial disease on aspirin.
    van Geffen JP; Kleinegris MC; Verdoold R; Baaten CC; Cosemans JM; Clemetson KJ; Ten Cate H; Roest M; de Laat B; Heemskerk JW
    Thromb Res; 2015 Mar; 135(3):513-20. PubMed ID: 25600441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study.
    Pathansali R; Smith NM; Bath PM
    Platelets; 2001 May; 12(3):144-9. PubMed ID: 11304415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.